drugset / Trial / NCT00527514
Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will be conducted to assess the efficacy and safety of an amlodipine/olmesartan treatment regimen in stage 1 and stage 2 hypertensive subjects.
Timeline
- Start
- 2007-09
- Primary completion
- 2008-04
- Completion
- 2008-04
Outcome
Met primary endpoint
registry MEAN Overall Active Treatment Period: -21.4 (Standard Deviation 0.80) mm Hg NCT00527514 ↗
registry analysis (superiority or other test); Overall Active Treatment Period; p <0.0001; one-sample t-test; note: No multiplicity adjustments NCT00527514 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlodipine | Other / unclassified | — | — |
| Subject | Olmesartan medoxomil | Unknown | — | — |